Search | Clinical Trials Finder

Conditions: Premature Birth, Neurodevelopmental Disorders, Brain Development Abnormality, Brain Lesion
Interventions: MRI, Neurodevelopmental/Neuropsychological Assessment; Diagnostic Test
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 8 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions: Not listed
Lead sponsor: Richard Frye; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Abnormalities, Failure to Thrive, Mental Retardation, Microcephaly
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Biospecimen Donation, Brain Injury, Brain Diseases
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2075
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions: MINI-KID; Other
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Autism Spectrum Disorder, Fra(X) Syndrome
Interventions: specimen collection; Other
Lead sponsor: Nova Mentis Life Science Corp; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Sickle Cell Disease
Interventions: Sickle Cell Collaboration for Child Development; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Months to 31 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Fragile X Syndrome, Autism Spectrum Disorder, Autistic Disorder, Asperger Syndrome
Interventions: Alpha Auditory Entrainment, Sham; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 10 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Developmental Delay Disorders, Chromosome Deletion, Mental Retardation, Sleep Disorders, Circadian Rhythm, Self Injurious Behavior
Interventions: dTR Melatonin (NIH CC PDS), Phototherapy (Bright Light), Melatonin CR; Drug · Device
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autism Spectrum Disorder
Interventions: transcranial magnetic stimulation; Device
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 13 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Autism Spectrum Disorder, Fragile X Syndrome
Interventions: Mismatch negativity; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fragile X Syndrome
Interventions: Sertraline, Placebo; Drug
Lead sponsor: Randi J. Hagerman, MD; Other
Eligibility: 24 Months to 68 Months
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities, Developmental Delay (Disorder), Cerebral Palsy (CP), Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment, Cerebral Palsy Infantile, Cerebral Palsy Spastic Hemiplegic, Cerebral Palsy, Dyskinetic, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD, Hypoxic Ischemic Encephalopathy, Hypoxic Ischemic Encephalopathy (HIE), Traumatic Brain Injury (TBI), Sensory Processing Disorder, Chromosomal Abnormalities, Genetic Disorders, Down Syndrome (Trisomy 21), Fragile X Syndrome (FXS), RETT Syndrome With Proven MECP2 Mutation, Williams Syndrome, 22q11.2 Deletion Syndrome, Sensorimotor Integration
Interventions: Not listed
Lead sponsor: Healing Hope International; Other
Eligibility: 4 Years to 12 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Rett Syndrome
Interventions: NNZ-2566, Placebo; Drug
Lead sponsor: Neuren Pharmaceuticals Limited; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Saint Paul, Minnesota • Houston, Texas

Conditions: Neurodevelopmental Disorders
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 0 Months to 99 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Tuberous Sclerosis, Autism Disorder, Intellectual Disability
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 3 more

Conditions: Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence, Tic Disorder, Childhood, Tics
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 8 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cerebral Palsy, Myelomeningocele, Arthrogryposis, Motor Skills Disorders, Gross Motor Development Delay
Interventions: adapted Chicago Run running program; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Chicago Heights, Illinois

Conditions: Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
Interventions: Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Tuberous Sclerosis Complex
Interventions: Not listed
Lead sponsor: Translational Genomics Research Institute; Other
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome (FAS), Alcohol Related Neurodevelopmental Disorder, Alcohol Use Complicating Pregnancy, Unspecified Trimester
Interventions: Positive FASD education brochure, Negative FASD education brochure, Active comparator (a general women's health brochure); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome
Interventions: Everolimus blinded oral capsules, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Rett Syndrome
Interventions: TSHA-102; Genetic
Lead sponsor: Taysha Gene Therapies, Inc.; Industry
Eligibility: 2 Years to 3 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts

Search by objective public record fields.

Childhood Outcomes of Preterm Brain Abnormalities

Patterns of Neurodevelopmental Disorders

Evaluation of Patients With Unresolved Chromosome Abnormalities

University of Central Florida CereBank

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Testing the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention

Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders

Treatment Strategies for Children With Smith-Magenis Syndrome

Abnormal Connectivity Involving the Social Reciprocity Network in Autism and the Impact of Neurostimulation in Mitigating the Abnormalities

Speech-in-noise Perception in Autism and Fragile X

Trial of Sertraline to Treat Children With Fragile X Syndrome

Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

Etiology and Early Diagnosis of Neurodevelopmental Disorders

Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)

Tourette Discrimination (TD) Stigma Scale

Ready, Set, Go! A Physical Fitness Intervention for Children With Mobility Challenges

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

Studies in Patients With Tuberous Sclerosis Complex

Development of Education Materials for Prevention of FAS in Russia

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome